Co-trimoxazole (trimethoprim-sulfamethoxazole) is a widely available antibiotic that substantially reduces HIV-related morbidity and mortality in both adults and children. Prophylaxis with co-trimoxazole is a recommended intervention of proven benefi t that could serve not only as an initial step towards improving paediatric care in young children with limited access to antiretroviral treatment, but also as an important complement to antiretroviral therapy in resourcelimited settings. Despite co-trimoxazole's known clinical benefi ts, the potential operational benefi ts, and favourable recommendations by WHO, UNAIDS, and UNICEF, its routine use in developing countries-particularly subSaharan Africa-has remained limited. Out of an estimated 4 million children in need of co-trimoxazole prophylaxis (HIV-exposed and HIV-infected), only 4% are currently receiving this intervention. We discuss some of the major barriers preventing the scale-up of co-trimoxazole prophylaxis for children in countries with a high prevalence of HIV and propose specifi c actions required to tackle these challenges.
Introduction
At the end of 2006, there were an estimated 2·3 million children worldwide living with HIV, an estimated 530 000 new HIV infections occurred, and 380 000 children died from AIDS. 1 An estimated 780 000 children are in urgent need of antiretroviral therapy (ART) and this number is constantly increasing. 2, 3 Most of these children live in sub-Saharan Africa, where only 10% currently access treatment. [2] [3] [4] [5] [6] Despite the growing intensity of current eff orts to off er ART to children living in resource-limited settings, substantial obstacles remain, which include: limited training and experience of providers in treating children; the lack of practicable, easy-to-use paediatric antiretroviral form ulations; no fi xed-dose combinations making treatment more diffi cult to administer and adhere to; 7 the high cost of paediatric antiretroviral drugs that may be up to ten times more expensive than the corresponding adult formulations; 8 and the lack of aff ordable and simple technologies for confi rming HIV infection in children under 18 months of age. It is therefore likely to be some time before infrastructure and resources permit many more children to access lifesaving ART.
In the meantime, co-trimoxazole (trimethoprimsulfamethoxazole) is a recommended intervention of proven benefi t that could improve paediatric care in young children and act as an important complement to ART in resource-limited settings.
Benefi ts of co-trimoxazole prophylaxis in HIVinfected infants and children
Co-trimoxazole is a widely available, easy to administer, safe, and low-cost antibiotic that still appears as a fi rstline drug on formularies of developing countries. It has a broad-spectrum prophylactic action against common bacterial pathogens, Pneumocystis jirovecii (formerly Pneumocystis carinii) , and protozoa such as Plasmodium spp and Isospora belli. Randomised controlled trials (RCTs) 9, 10 and studies with historical controls [11] [12] [13] [14] [15] [16] in HIVinfected African adults consistently show signifi cant benefi ts in survival for those receiving co-trimoxazole prophylaxis. These improvements in survival have been accompanied by substantial reductions of severe disease events and the number of hospital admissions linked to invasive bacterial disease, pneumonia, malaria, and diarrhoea, although disease-specifi c benefi t has varied between studies. 9.10,14,16 The only RCT done in children was in HIV-infected Zambian children aged 1-14 years, which found a highly signifi cant benefi t of co-trimoxazole in improving survival and reducing hospitalisations and pneumonia (hazard ratio 0·57 [95% CI 0·43-0·77], p=0·0002). 17 Many of the studies showing benefi t have been in communities where in-vitro co-trimoxazole resistance to common bacterial isolates is already high. 14, [16] [17] [18] It is well recognised that P jirovecii is a common cause of pneumonia and death in HIV-infected infants. [19] [20] [21] [22] The introduction of routine co-trimoxazole prophylaxis for infants at risk of HIV infection in several countries has been very eff ective in preventing P jirovecii pneumonia, which could in itself prevent a third to a half of all HIVrelated deaths in African infants. 23 In addition to the clinical benefi ts of co-trimoxazole, there are several potential operational advantages. First, mothers are more likely to bring children to health-care centres for HIV testing and follow-up care if they know that an eff ective treatment is immediately available. This could also provide an opportunity to address HIV-related prevention and care issues for the mother and other family members. Second, co-trimoxazole prophylaxis provides an opportunity for systematic care of children at health facilities at lower levels of the health system and the observed stabilising eff ect on immune function and viral replication has the biological potential to delay the need for ART until it is available.
14 Third, co-trimoxazole could serve as a backbone for establishing and strengthening a chronic care infrastructure upon which interventions including ART could be built, since systematic delivery of co-trimoxazole requires a healthcare delivery system that will not only identify HIV-Review infected children but also ensure that they remain in the system. Fourth, co-trimoxazole prophylaxis provides an opportunity to model drug adherence approaches before starting ART. 24, 25 Finally, co-trimoxazole prophylaxis is costeff ective and could have important benefi ts for other family members. 26, 27 Co-trimoxazole has known clinical benefi ts, potential operational benefi ts, and is also recommended by WHO, UNAIDS, and UNICEF 23, 28 for all HIV-exposed and HIVinfected children until reliable confi rmation of HIV status has been made. However, the drug's routine use in resource-limited settings-particularly sub-Saharan Africa-has remained limited. Out of an estimated 4 million children who are in need of co-trimoxazole prophylaxis (HIV-exposed and HIV-infected), only 4% are currently receiving this intervention. 29 We discuss some of the major barriers preventing the scale-up of cotrimoxazole prophylaxis for children in countries with a high prevalence of HIV and suggest specifi c actions to tackle them. Although these actions are proposed for highprevalence, resource-limited settings, they may be more widely relevant.
Barriers preventing scale-up of co-trimoxazole prophylaxis in infants and children
Hypothetical objections against widespread use of co-trimoxazole in high HIV-prevalence countries Scaling-up co-trimoxazole as part of the minimum package of care in Africa was initially hampered by a number of legitimate concerns. The provisional WHO/ UNAIDS recommendations for Africa released in 2000 30 were made on the basis of two studies, 9,10 both from Abidjan, Côte d'Ivoire, where at the time prevalence of bacterial resistance to co-trimoxazole was low. Clinicians and policymakers in Africa therefore doubted the effi cacy of co-trimoxazole in countries where co-trimoxazole resistance was known to be high, and so did not accept or apply the provisional recommendations. Since then, several studies have shown that co-trimoxazole prophylaxis improves survival and reduces serious disease events even in areas of Africa where in-vitro cotrimoxazole resistance is common. [12] [13] [14] [15] [16] [17] Furthermore, although resistance levels increase with time, as they have in Abidjan, this has not prevented the drug from being useful. 18 Co-trimoxazole's effi cacy against pneumocystis, isospora, and malaria might explain its favourable eff ects on morbidity and survival in endemic areas.
Other major concerns of co-trimoxazole prophylaxis were that widespread use of the drug would accelerate the spread of multidrug resistance among common bacterial pathogens and increase resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine and other antifolate antimalarial drugs. From a broader publichealth perspective, this could mean reducing useful life of cheap and available fi rst-line therapies; from the individual clinical management perspective there are concerns that, for example, a patient with malaria would be more likely to fail treatment with sulfadoxinepyrimethamine if already taking co-trimoxazole prophylaxis. However, an RCT in children aged 5-15 years in Mali showed that co-trimoxazole prophylaxis does not appear to select for sulfadoxine-pyrimethamine-resistant P falciparum. 31 Furthermore, since sulfadoxinepyrimethamine is being phased out and replaced by more eff ective artemisinin-based combination therapies in most countries, concerns about antimicrobial resistance to sulfadoxine-pyrimethamine might become less relevant.
By contrast, uncertainty remains about the possible impact of co-trimoxazole prophylaxis on the prevalence of antibiotic-resistant bacteria, with studies so far showing confl icting results for enteric isolates. 29, 32 Since most of these studies were not specifi cally designed with the primary intention of studying drug resistance as a function of prophylaxis, the evidence base is not powerful enough to dismiss the risk of resistance developing, and specifi c ongoing surveillance is therefore justifi ed. The potential problem is not only for increased resistance to co-trimoxazole, which is already high in many settings, but also for worsening resistance to other antibiotics. 33 However, co-trimoxazole prophylaxis may protect against development of resistance if it reduces the number of hospital admissions and the frequency of use of other antibiotics.
Actions required
There is a need for consultative forums within countries that bring together key stakeholders at a national level, to disseminate information on current evidence, bridge gaps in knowledge, allay fears on use of co-trimoxazole at country level, and present the rationale for current recommendations. 29 The forums should also serve to boost leadership and to prepare the next steps for implementing a phased national co-trimoxazole scale-up plan that is integrated into child survival programmes. Focus should be placed on the following: a national coordination mechanism that is inclusive of all major actors; a district and facility-based scale-up plan that includes a clear defi nition of needs, targets, and required budgets; a national drug procurement and distribution system that includes drugs and commodities for paediatric care including co-trimoxazole; and a system of monitoring the number of adults and children accessing co-trimoxazole, which will be needed for forecasting drug orders.
There is undoubtedly international importance in setting up surveillance monitoring programmes to follow microbial resistance emergence (eg, in enteric bacteria, Plasmodium spp, and pneumocystis) and to assess the ongoing effi cacy of widespread co-trimoxazole prophylaxis programmes. Research is also needed to evaluate the effi cacy of other antimicrobial agents for reducing morbidity and mortality of HIV-related Review infections in high HIV-prevalence countries (with and without malaria). As microbial resistance increases, we will need to know whether other eff ective prophylactic regimens can be implemented and how this might be done on a large scale. Future scenario modelling and health economic assessments will be needed to gather this information.
Inadequate policy guidance on co-trimoxazole prophylaxis
The provision of HIV/AIDS care in the low-resource setting has mainly focused on antiretroviral drugs for treatment of HIV and for prevention of mother-to-child transmission (PMTCT) of HIV. Little or no consideration has been given to co-trimoxazole prophylaxis. ART provision has also focused mainly on adults, and since policy guidance on co-trimoxazole is usually integrated within such guidelines, there is a resulting lack of guidance on co-trimoxazole prophylaxis for infants and children at the national level. Since 2006, WHO has begun to produce guidelines for use of co-trimoxazole and ART in infants and children.
Actions required
National policy guidelines on co-trimoxazole prophylaxis are required that explicitly separate adults and children. Panel 1 and panel 2 specify criteria for when to initiate and when to discontinue co-trimoxazole prophylaxis. Guidelines also need to clearly defi ne doses for split-dose tablets and if available, syrups or soluble formulations (table) . Training on co-trimoxazole prophylaxis for children and adults needs to be incorporated into the HIV/AIDS-related training curriculum taught to clinicians, nurses, and other care providers. The co- 
Universal option
Prophylaxis for all infants and children born to mothers confi rmed or suspected of living with HIV. This strategy may only be considered in settings with a high prevalence of HIV, high infant mortality caused by infectious diseases, or limited health infrastructure *Adapted from WHO guidelines. 23 †Defi ned as a child born to an HIV-positive mother or a child breastfeeding from an HIV-positive mother until HIV exposure stops (6 weeks after complete cessation of breastfeeding), and infection can be excluded. ‡In children younger than 18 months, HIV infection can only be confi rmed by virological testing. For children older than 18 months, HIV infection can be confi rmed by HIV antibody testing. §Once a child is started on co-trimoxazole, treatment should continue until 5 years of age regardless of clinical symptoms or CD4 percentage. Specifi cally, infants who begin co-trimoxazole prophylaxis before the age of 1 year and who subsequently are asymptomatic and/or have CD4-cell count ≥25% should remain on co-trimoxazole prophylaxis until they reach 5 years of age. ¶Countries may choose to adapt a CD4 threshold of 200 cells/μL where Pneumocystis jirovecii and toxoplasmosis are the major targets for co-trimoxazole prophylaxis and where bacterial infections and malaria are not prevalent.
Panel 2:
Recommendations for discontinuing co-trimoxazole in infants and children* HIV-exposed children Discontinue co-trimoxazole prophylaxis after HIV infection is excluded †
Infants and children with HIV ‡

Until age 5 years
CD4 testing not available:
• Do not discontinue co-trimoxazole prophylaxis, particularly in settings where bacterial infections and malaria are common HIV-related events
• Consider discontinuing co-trimoxazole prophylaxis in children with evidence of good clinical response to ART (absence of clinical symptoms for at least 1 year of therapy), good adherence, and secure access to ART CD4 testing available:
• In countries where co-trimoxazole prophylaxis is recommended only for preventing Pneumocystis jirovecii and toxoplasmosis, it can be discontinued with evidence of immune recovery on ART (CD4-cell count ≥200cells/μL after at least 6 months of ART) • In countries with a high prevalence of bacterial infections and malaria, discontinue co-trimoxazole prophylaxis in children with evidence of immune recovery related to ART (CD4-cell count ≥350 cells/μL after at least 6 months of ART) ART=antiretroviral therapy. *Adapted from WHO guidelines. 23 †In children younger than 18 months, HIV infection can only be confi rmed by virological testing. For those older than 18 months, HIV infection can be confi rmed by HIV antibody testing. ‡Applies only to discontinuation related to immune restoration on ART.
Review trimoxazole policy should also be incorporated into guidelines and ongoing training involving integrated management of childhood illnesses (IMCI), PMTCT, tuberculosis, and HIV/AIDS care.
Limited identifi cation and recruitment of HIV-exposed and HIV-infected children for co-trimoxazole
Opportunities for early identifi cation of HIV-exposed children are limited for three main reasons. First, coverage of PMTCT programmes in countries with a high prevalence of HIV remains low, 29 meaning that most HIV-exposed infants are not being identifi ed or are being lost from the health system. 34 Second, countries with a high burden of HIV have not maximised the opportunity of child-health programmes such as the Expanded Program of Immunisation (EPI) to identify HIV-exposed children. For example, in Swaziland where the antenatal HIV prevalence rate is particularly high (estimated to be 42%), about four out of every ten children attending EPI and child clinics could be considered HIVexposed. Of these children, one to two are likely to be HIV-infected and could benefi t from early HIV testing, co-trimoxazole, and ART. Finally, the high possibility of obtaining false-positive results from antibody-based rapid HIV tests in children under 18 months of age born to HIV-positive mothers in resource-limited settings makes it diffi cult to determine infection in HIV-exposed children. This problem is a major policy bottleneck for early administration of co-trimoxazole prophylaxis and ART, 24 since health systems in some countries are unwilling to provide co-trimoxazole to children unless HIV infection is confi rmed. Furthermore, care providers at diff erent levels of the health system have not been adequately trained to be able to maintain a high index of suspicion for recognition of signs and symptoms suggestive of HIV infection in children. Opportunities for active recruitment have also been grossly under-used or missed in voluntary counselling and HIV-testing sites, clinics for under-5-year-olds, the general out-patient department, and sites visited by people at high risk of HIV infection, such as tuberculosis clinics, paediatric wards, and paediatric nutritional rehabilitation units.
Actions required
Eff orts should be made to rapidly accelerate the expansion of PMTCT services as an essential component of routine maternal and child-health services at all levels of the health system. This action would allow early detection of HIVpositive mothers and children eligible for both ART and co-trimoxazole prophylaxis. Advocacy for the development of specifi c, easy-to-use, and aff ordable HIV diagnostics for identifying HIV infection in children under 18 months of age is urgently required. At the moment, the only way of confi rming HIV infection in this age-group is through virological antigen testing (eg, with PCR), which is only available in a few countries or at limited sites. In practice, this poses a practical dilemma to policymakers and clinicians in most countries, since it means one of two choices: (1) blanket administration of co-trimoxazole to all children under 18 months of age born to HIV-positive mothers in line with WHO/UNICEF recommendations, or (2) waiting until the HIV status is confi rmed at 18 months, by which time infection-related mortality, including mortality caused by P jirovecii pneumonia, would have taken its toll on a large proportion of HIVinfected children. 23 Where PCR is available, eff orts should be made to test the infant 6 weeks after cessation of breastfeeding to eff ectively target continuation of co-trimoxazole to only infants that have confi rmed infection. In settings where PCR is not yet available, in light of high mortality, infants and children under the age of 18 months should be promptly off ered co-trimoxazole and considered for ART on a presumptive basis until a defi nitive HIV diagnosis is made after 18 months. 4, 35 For countries where logistic and other operational constraints challenge the feasibility of off ering co-trimoxazole to all HIV-exposed children under 18 months of age, a compromise strategy would be to off er co-trimoxazole to all children born to HIV-positive mothers from 4-6 weeks until 6 months of age, when the risk of P jirovecii pneumonia-related mortality is highest. 23 Clinicians, nurses, and care providers need training to recognise possible HIV-related clinical features in infants and young children at all sites where there is contact with children. In settings where HIV prevalence is high, such 
HIV testing in these three specifi c groups needs to move towards an "opt-out" or active approach that is health-provider initiated. 36 For pregnant women attending PMTCT programmes, HIV testing should be off ered routinely as part of a standard screening package (provider-initiated testing and counselling [PITC] ). Understandably, the barriers preventing the scale-up of HIV testing in pregnant women in diff erent countries might be highly contextual and scalability, acceptance, and feasibility might vary. However, experience from Botswana 37, 38 and Zimbabwe 39 shows that introduction of a PITC approach in antenatal services with rapid, same-day results greatly increases uptake of HIV testing and the percentage of women receiving PMTCT interventions. These fi ndings highlight the potential public-health impact of introducing PITC within programmes that attempt to increase the number of people with access to HIV prevention and treatment services. Thus, despite the myriad of potential logistic and social barriers to HIV testing that might exist in diff erent contexts, introducing the PITC approach would be the fi rst important step for increasing acceptance and knowledge of HIV status as well as uptake of PMTCT interventions. For infants and children who present with symptoms or signs that could be attributable to HIV infection, HIV testing should be routinely off ered in an opt-out manner as part of the diagnostic work-up for patients and a basic standard of care (diagnostic HIV testing and counselling, DTC). High-risk sites such as tuberculosis clinics, paediatric wards, and nutritional rehabilitation units should be considered a priority for DTC because this will increase the chance of HIV casefi nding in children. For example, a study in Botswana showed that 60% or more children admitted to paediatric wards in major hospitals were HIV-positive. 40 In such a country, moving to an active DTC strategy could increase the number of children identifi ed as HIV-postitive and improve their eventual outcomes in terms of morbidity and mortality. 40 HIV-testing guidelines need to include explicit guidance on PITC and DTC, and counsellors and care providers must be adequately trained. 35 
Prescriptions of co-trimoxazole prophylaxis are restricted to isolated HIV/AIDS clinics
Although identifi cation of HIV-exposed infants and HIVinfected children might occur at diff erent sites in the health system, patients are often obliged to present themselves to specialised HIV/AIDS clinics, often located in hospital settings, if they are to receive a prescription of co-trimoxazole prophylaxis. This means additional waiting times in queues, the need for separate visits, or long distance travel to hospitals for monthly prescription refi lls. The latter is an important barrier for those committed to continuing prophylaxis; one of the main reasons for stopping prophylaxis is the high cost of transport to distant health facilities. 41 It is much more convenient to provide a 3-month rather than 1-month supply of drugs when distance and transport costs are issues and this is likely to improve adherence.
Actions required
An integrated one-stop service that provides cotrimoxazole prescriptions at all sites where there is contact with children would foster a patient-friendly approach. In particular, children who are born to HIVinfected mothers or children identifi ed as being HIVpositive through voluntary counselling and HIV-testing clinics, clinics for under 5-year-olds, the general outpatient department, tuberculosis clinics, or nutritional rehabilitation units should be given a prescription of cotrimoxazole (on site) for their mothers to take to the pharmacy for collection of the drugs provided there are no contraindications.
To improve access for continued co-trimoxazole prophylaxis, drug refi lls should be made readily available at decentralised sites including health centres and homebased care programmes. All health workers or members of multidisciplinary care teams should be able to prescribe co-trimoxazole.
Inadequate information, education, and communication advocating co-trimoxazole
Because of policymakers' concerns about eff ectiveness and development of drug resistance following widespread use of co-trimoxazole at country level, little or no emphasis had been placed on developing specifi c information, education, and communication messages advocating co-trimoxazole within health services or the community. Individuals that use health services might therefore be insuffi ciently aware of the benefi ts of cotrimoxazole prophylaxis.
Actions required
There is an urgent need to develop specifi c messages to increase awareness and the demand for co-trimoxazole both among health workers and in the community. Such messages should be simple and clear-for example, "taking your daily doses of co-trimoxazole could provide Review you with protection from a number of common HIVrelated illnesses including malaria and diarrhoea, considerably reducing your risk of death from HIV/AIDS, therefore providing you with benefi ts before starting ART and also while on ART".
Motivational talks advocating the use of co-trimoxazole in the community and within diff erent health services should be routinely done by a joint team of health workers and people living with HIV/AIDS.
Problems with co-trimoxazole drug supply and monitoring
Most national programmes do not have systems for accurately estimating programme needs or for monitoring consumption related to prophylaxis. Co-trimoxazole drug supplies provided to health facilities are used rather blindly for both treatment and prophylaxis. Cotrimoxazole stock shortage is therefore a common operational problem that directly hampers initiating and continuing prophylaxis. For example, in a recent national survey in Malawi at 94 public-health facilities providing ART, 55% of facilities were out of stock of co-trimoxazole at the time of the supervisory visit (HIV Unit, Ministry of Health, Malawi, unpublished data).
Actions required
An initial estimate of national requirement would need to be calculated to decide how much co-trimoxazole is required as a "kick-start" for central medical stores. The pharmacy in each health facility should centralise supplies of co-trimoxazole for patients and should keep a "vital register" of co-trimoxazole prophylaxis. Patients should be given a unique co-trimoxazole registration number and this number plus name, age, and sex should be listed on the register. The unique registration number will also be written on the patient card or health passport if this exists. Every time a patient is given cotrimoxazole, the date should be entered into the register. Therefore, the number of patients (adults and children) who start co-trimoxazole and the number who continue co-trimoxazole can be monitored by regular checks of the vital register. The use of such registers merits pilot testing and would certainly help with logistics of procurement and distribution.
Co-trimoxazole should be supplied through existing drug distribution systems and should be provided free of charge. Districts will need to ensure that a "budget line" is created for co-trimoxazole prophylaxis and that there is an uninterrupted supply of the drug for both treatment and prophylaxis. There will be a need to designate a responsible authority at national level who monitors the scale-up of co-trimoxazole prophylaxis.
Lack of implementation plans and targets for children
Few countries have so far drawn up phased implementation plans and a system for monitoring and reporting of progress.
Actions required
A phased plan for scale-up and integration of cotrimoxazole prophylaxis in children within existing child-care and HIV services, including specifi c population targets and indicators, should be developed. A minimum set of indicators could include: the existence of an eff ective national coordination mechanism; existence of a national policy on co-trimoxazole prophylaxis; a co-trimoxazole scale-up plan, with budgetary allocation; the proportion of HIV-exposed infants in PMTCT programmes who receive cotrimoxazole prophylaxis at 6-8 weeks; and the proportion of HIV-infected children within existing health services (including paediatric HIV care, IMCI, nutritional rehabilitation units, and home-based care) who access co-trimoxazole.
Although co-trimoxazole implementation could provide a useful and crucial entry point on which to build other interventions, by no means should it lead to the 
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propagation of a vertical co-trimoxazole programme. What is needed is to link co-trimoxazole as an integral part of a standard package of care within PMTCT, ART, and other child-health programmes, including distribution of insecticide-treated bednets for malaria prevention and safe-water vessels.
Programmatic issues and logistic/operational considerations
The main programmatic issues and actions required regarding the logistic and operational aspects linked to off ering co-trimoxazole prophylaxis in children are highlighted in panel 3.
Funding gaps in high HIV-prevalence settings
Although co-trimoxazole is cheap, large-scale implementation of co-trimoxazole prophylaxis in settings with a high prevalence of HIV will need substantial resources and logistics. With a conservative global estimate of 2·8 million children requiring co-trimoxazole in 2005 (2·3 million HIV-infected children and 530 000 new HIV infections), 1 this would amount to US$8·5-23 million per year on drug costs only, using an estimated annual cost of $3-8 per child.
Actions required
Development partners and donor countries should support widespread implementation of co-trimoxazole prophylaxis and ensure that co-trimoxazole is included as a specifi c component in funding proposals. Cotrimoxazole for HIV-exposed and HIV-infected children should be considered a priority intervention that is included in scale-up of paediatric HIV care and treatment.
Conclusions
There are considerable clinical and operational benefi ts of off ering co-trimoxazole prophylaxis to children in countries with a high prevalence of HIV. Serious eff orts need to be made to scale-up this widely available and easy-to-use medication.
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